MINNEAPOLIS, MN--(Marketwire - October 31, 2011) -
Highlighted Links |
|
|
BioDrain Medical, Inc. (OTCBB: BIOR) (OTCQB: BIOR), producer of the FDA cleared STREAMWAY System for automated surgical fluid disposal, announced today that a prestigious Minneapolis-based hospital has commenced with the use of the STREAMWAY system in its operating rooms.
The hospital is installing BioDrain’s unique automated system for safe and efficient disposal of surgical fluids and is training its operating room staff in the use of the unit. Through its continuous automated process, the STREAMWAY eliminates the need for multiple suction canisters and operative fluid collection and transport, greatly simplifying the standard complex procedures for protection from and disposal of infectious fluids generated in surgical settings, while reducing operational costs.
Kevin Davidson, Chief Executive Officer of BioDrain, stated, “We are very pleased that this outstanding medical center, with over 20 operating rooms, has recognized the important safety, efficiency and cost benefits of the BioDrain STREAMWAY system. This hospital represents a very strategic relationship for our Company, and we are very excited to add it to the number of outstanding institutions that have accepted the STREAMWAY as a significant advance in surgical procedures and protocols.”
Mr. Davidson added, “To date, more than 600 surgeries have been completed using the STREAMWAY System. Our current production ramp-up of more STREAMWAY units will allow us to demonstrate the system to more hospitals across the nation and accelerate the pursuit of our substantial number of potential orders.”
About BioDrain Medical, Inc.
BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers’ exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today’s manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain’s STREAMWAY System fully automates the collection, measurement and disposal of surgical fluids resulting in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving the Occupational State and Health Association (OSHA) and other regulatory compliance, and 3) improving the efficiency of the operating room (and thereby making surgeries more profitable).
BioDrain’s STREAMWAY System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain’s STREAMWAY System, the number of canisters can be significantly reduced. BioDrain Medical, Inc. makes the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For additional information, please visit: www.biodrainmedical.com.
Forward-looking Statements:
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company’s business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the company’s ability to implement its long range business plan for various applications of its technology; the company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the company’s reports filed with the Securities and Exchange Commission. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company’s financial position. See the company’s most recent Quarterly Report on Form 10-Q and related 8-K filings.
Investor Relations Contact:
Stanley Wunderlich
Consulting for Strategic Growth 1 Ltd.
Tel: 800-625-2236 ext. 7770
Email: info@cfsg1.com